Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$41.82
Change (%) Stock is Down 0.27 (0.64%)
Volume840,169
Data as of 05/29/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 95 employees.More >>

Recent NewsMore >>
DateTitle 
05/29/15Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib
--Oral, Dual Syk-JAK Kinase Inhibitor Continues to Demonstrate Clinical Proof of Concept in Hematologic Cancer Patients Who Have Failed Prior Therapies-- SOUTH SAN FRANCISCO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced updated positive safety and efficacy data from the Phase 1 part of its ongoing Phase 1/2a proof-of-concept study of cerdulatinib in patients with hematologic cancers who have failed multiple therapies. Cerdulatinib is an oral, du... 
Printer Friendly Version
05/18/15Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology (ASCO) Annual Meeting
--Updated Safety and Efficacy Data From Phase 1 Part of Ongoing Phase 1/2a Study to be Presented-- --Company Opens Enrollment in Expansion Cohorts in Phase 2a Part of Study-- SOUTH SAN FRANCISCO, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will present updated safety and efficacy data from the Phase 1 part of its ongoing Phase 1/2a proof-of-concept study of cerdulatinib in patients with hematologic cancers who have failed multipl... 
Printer Friendly Version
05/06/15Portola Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2015. "This is a monumental year for the company," said William Lis, chief executive officer of Portola. "We are now approximately one year from the potential launch of our first commercial product, andexanet alfa, in 2016 followed by a second product... 
Printer Friendly Version
05/05/15Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases
Collaboration Allows Portola to Advance Product Candidates Outside of Core Focus While Retaining Economics and Flexibility for Future Development SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced a collaboration with Ora, Inc. for the development of Portola's highly selective Syk inhibitor, PRT2761, in ophthalmic diseases. The inhibition of Syk may more completely prevent activation of mast cells in ocular allergy and, therefore, ... 
Printer Friendly Version
05/05/15Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, at 10:00 a.m. Pacific Time in Las Vegas. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharma... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
06/16/15 10:00 a.m. PT
Portola Pharmaceuticals, Inc. Annual Shareholder Meeting
LocationPortola’s offices at 270 East Grand Ave.
South San Francisco, CA

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.